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warranted to identify steps for increasing treatment 
effectiveness in these patients.
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OBJECTIVES: Prior results from the TACTICS-TIMI 
18 trial demonstrated that an early invasive approach 
to the management of patients with unstable angina 
(UA) or non-ST-segment elevation myocardial infarction
(NSTEMI) was cost-effective, with an estimated cost per
life-year gained of $8371; for high-risk patients with ST-
segment changes at baseline, $3224 per life-year gained.
We examined the joint inﬂuence of diabetes and ST-
segment changes on the cost-effectiveness of the early
invasive strategy. METHODS: Inpatient hospital costs for
the 1722 US, non-VA patients for the 6-month trial
period were obtained from the UB92 and Medicare
cost/charge ratios. Other costs included: physician, 
outpatient, medication, and productivity costs. Life-
expectancy estimates for patients with acute MI/coronary
heart disease from the Framingham Heart Study were
used for patients who survived the trial with/without
experiencing a non-fatal MI. Cost-effectiveness was eval-
uated in terms of cost per life-year gained. Regression
analyses of the net monetary beneﬁt across a range of
ceiling ratios were used to obtain cost-effectiveness
acceptability curves for subgroups deﬁned by diabetes
and ST-change status. RESULTS: Net monetary beneﬁt
regression analyses revealed a three-way interaction
between diabetes, ST-changes and treatment group which
approached signiﬁcance (p < 0.10) for models based on a
ceiling ratio of $14,000–$49,000. Associated cost-
effectiveness acceptability curves suggest a probability
that the invasive strategy is cost-effective for non-diabetic
patients with ST-segment changes of >95% for ceiling
ratios $4000 per life-year gained. At a ceiling ratio of
$50,000, the probability of cost-effectiveness for diabetic
patients without ST-changes is 56%, for diabetic patients
with ST-changes, 73%, and for non-diabetic patients
without ST-changes, 74%. CONCLUSIONS: In addi-
tion to ST-segment changes at presentation, the cost-
effectiveness of an invasive strategy for patients with UA
or NSTEMI varies by DM status. This analysis demon-
strates the usefulness and efﬁciency of net-beneﬁt regres-
sion for the evaluation of cost-effectiveness for different
patient subgroups.
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OBJECTIVES: To compare the effectiveness of two
widely prescribed agents, amlodipine and valsartan, in
blood pressure lowering and control in a multi-center
ambulatory practice setting. METHODS: All adult hyper-
tensive patients were identiﬁed from 1998 to 2001 from
a large commercially available electronic medical record
covering over 360,000 US primary care patients. Study
patients were required to have initiated therapy with
either amlodipine or valsartan and to have at least one
BP measurement within 6 months preceding and 12
months following the index date. Mean change in systolic
blood pressure (SBP) and rates of JNC VI BP goal 
attainment were compared using multivariate statistics.
RESULTS: One thousand one hundred seventy-ﬁve
amlodipine and 512 valsartan patients met criteria. Base-
line SBP was 159.5mmHg for amlodipine; 159.9 for 
valsartan. Overall, amlodipine was associated with 
an adjusted mean change of -16.6mmHg in SBP (95%
CI-17.7, -15.5) vs. -13.4mmHg for valsartan (95% 
CI-15.1, -11.7; p = 0.002). Approximately 43% of
amlodipine patients achieved JNC VI goal vs. 33% in the
valsartan treated cohort (p = 0.030). Among patients on
complex antihypertensive regimens (2 or more agents),
amlodipine was associated with an adjusted mean change
of -16.6mmHg (95% CI -18.5, -14.8) vs. -10.0mmHg
for valsartan (95% CI -12.8, -7.2; p < 0.001). Within
this subgroup, JNC VI goal attainment was 43% vs. 36%
for amlodipine vs. valsartan (p = 0.095). CONCLU-
SIONS: In monotherapy and in combination, amlodipine
demonstrated both a statistically signiﬁcant and clinically
meaningful improvements in SBP change and JNC VI goal
attainments vs. valsartan, particularly among patients on
complex antihypertensive regimens. Although these data
must be interpreted within the limitations of the obser-
vational study design, this study suggests that amlodipine
may be used in a variety of therapeutic combinations 
and among a broad spectrum of hypertensive adults to
improve SBP control and goal attainment.
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OBJECTIVES: Generation of population cost estimates
for event-time data requires a sophisticated approach 
to account for the probability of incurring the event over
time. This research investigated the relationship of donor
and recipient factors with all-cause renal graft failure and
estimates of the cost of failure from a Medicare perspec-
tive. METHODS: A two-part econometric approach 
was used to determine Medicare claims attributable to all-
cause graft failure (including deaths). First, type-speciﬁc
hazard functions were estimated with Cox proportional
hazards models. Using data from USRDS for primary
renal transplants in adults between 1993-1998, we devel-
oped separate predictive models for transplants from
living and cadaveric donors after identifying covariates
associated with graft loss. Models were stratiﬁed by trans-
plant year and included donor and recipient characteris-
tics plus clinical variables including immunosuppression
therapies. Next, the log-transformed costs for patients
who experienced the event were modeled against the
covariates to estimate costs speciﬁcally associated with
failure at a given time point. For patients who did not
experience the event, predicted costs were generated
based on the model coefﬁcients and individual covariates.
Retransformation of the log costs included an adjustment
using residual smearing. The expected Medicare claims
associated with graft failure were calculated by combin-
ing the estimated cumulative hazards of graft failure with
the smeared estimate of the claims associated with the
event. RESULTS: For living donor transplants (N =
5831), expected Medicare claims attributed to renal
transplant graft failure were approximately $13,073 ±
$14,318 (median = $8,933; range = $560–$191,169) at
3 years post-transplant. For cadaveric donor transplants
(N = 22,941), the expected Medicare claims were 
approximately $15,075 ± $13,149 (median = $11,540;
range = $699–$214,184). CONCLUSIONS: These esti-
mates provide groundwork for population-based studies
to address the cost-effectiveness of various treatments to
delay or prevent graft loss. The method allows policy-
makers to assess population costs after taking into
account the probability of event occurrence.
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Healthcare resource utilization (HCRU) may be evaluated
through patient interviews in multicenter clinical trials
but the accuracy of self-reported data should be assessed.
OBJECTIVE: This study evaluated the consistency
between electronic record data and patient self-reported
HCRU for herpes zoster (HZ) through telephone inter-
views. METHODS: HZ patients (N = 116) were recruited
from a managed care organization in Boston. HZ-related
hospitalizations, Emergency Department (ED) visits, 
outpatient visits and telephone calls were compared 
separately, with further differentiation among outpatient
contacts with primary care providers and specialists.
Medication use comparisons were made for analgesics,
antivirals and other prescription medications. Judgments
of consistency were based on intraclass correlation 
coefﬁcients (ICC) unless data were sparse. RESULTS:
Two patients with HZ hospitalizations were found in the
electronic records versus three in the questionnaire. Four
patients with ED visits were found in the electronic
records versus 34 in the questionnaire. The ICC for 
outpatient visits was 0.46 (CI 0.06-0.85; nelectronic records =
268, nZHEQ = 265). The ICC for telephone calls was 0.51
(CI 0.06–0.96; nelectronic records = 87, nZHEQ = 110). By out-
patient provider type, the ICC ranged from 0.27 for
primary care visits to 0.84 for specialist visits. ICCs of
0.55, 0.64 and 0.56 were found for pain medications,
antiviral medications, and other medications, respec-
tively. CONCLUSION: Patient self-reported HCRU 
reasonably (ICC ≥ 0.4), but imperfectly matched the elec-
tronic records across most categories, with no systematic
bias observed. Patient misclassiﬁcation of urgent care
visits as ED visits may account for some of the observed
discrepancies between ED and primary care visits. This
study, which represents one of the ﬁrst efforts to evaluate
the design of a patient self-report HCRU questionnaire
for use in clinical trials, identiﬁed limitations to compar-
isons between the two types of data sources and offers
insight into potential improvements for the design and
validation of such questionnaires.
MD3
THE IMPACT OF REQUIRING A FIXED PERIOD
OF ELIGIBILITY IN ECONOMIC AND
EPIDEMIOLOGICAL STUDIES THAT UTILIZE
LONGITUDINAL DATA
Eaton SC1, McQuay LJ1, Clark DW2, Paul JE1, Hauber AB3
1RTI Health Solutions, Research Triangle Park, NC, USA;
2GlaxoSmithKline, Inc, Research Triangle Park, NC, USA;
3RTI Health Solutions, Hatboro, PA, USA
OBJECTIVES: In economic and epidemiologic studies
utilizing longitudinal data, researchers often require a
ﬁxed follow-up period. By allowing differential follow-
up, researchers can eliminate one source of selection bias.
Our objective was to compare analyses of two study 
populations from the General Practice Research Database
(GPRD) differing only in length of follow-up time.
METHODS: Study population 1 (SP1; n = 28,643)
included patients with a given condition ﬁrst diagnosed
between June 1988 and February 1999. Study population
2 (SP2; n = 21,289) included only those patients in SP1
with at least a year of follow-up. Comorbid conditions,
resource use, and reasons for loss to follow-up were
